Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06034275 | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | PHASE1 | RECRUITING | 36 | — | — | Sep 13, 2023 | Dec 31, 2025 | Nov 15, 2024 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Dose Escalation of VIP943 (QW) | EXPERIMENTAL | Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW). |
| Dose Escalation of VIP943 (BIW) | EXPERIMENTAL | Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration twice weekly (BIW). |
| Name | Type | Description |
|---|---|---|
| VIP943 (QW) | DRUG | VIP943 will be administered by IV Infusion weekly |
| VIP943 (BIW) | DRUG | VIP943 will be administered by IV Infusion bi-weekly |
Inclusion Criteria: * Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies. * Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to ...